Pharma More Management
Pharma More Management has been active since 2010 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €71k and a net result of €15k. Equity is shrinking by ~15% per year across the filed fiscal years. Its solvency ranks better than 34% of 10963 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (low).
| Equity | €71k |
| Net result | €15k |
| Better than sector | 34% |
| Active | 15 yrs |
Strong profile, led by profitability.
All 5 axes are computed from data Checked has read.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 21.5% | 42.5% | |
| Net result | €15k | €6k | |
| Equity | €71k | €60k | |
| Gross operating margin | €55k | €29k | |
| Total assets | €331k | €175k |
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| Deposit | micro schema | micro schema | abbreviated schema | abbreviated schema | abbreviated schema |
| Revenue | - | - | - | - | - |
| EBITDA | €55k | €36k | €16k | €52k | €161k |
| Net profit | €15k | €1k | €-22k | €5k | €54k |
| Cash flow | €44k | €29k | €8k | €38k | €93k |
| Staff costs | - | - | €0 | €688 | - |
| Income taxes | €6k | €304 | €317 | €5k | €27k |
| Dividends | - | - | €0 | €800 | - |
| Total assets | €331k | €303k | €354k | €400k | €1.71M |
| Equity | €71k | €56k | €55k | €77k | €162k |
| Debt | €260k | €248k | €300k | €324k | €1.55M |
| of which ≤ 1y | €68k | €35k | €69k | €75k | €1.07M |
| of which > 1y | €192k | €211k | €229k | €246k | €471k |
| Working capital | €13k | €-12k | €-15k | €-10k | €251k |
| Employees (FTE) | - | - | - | 0.0 | 7.2 |
| 2025 | 2024 | 2023 | 2022 | 2020 | |
|---|---|---|---|---|---|
| Current ratio | 1.19 | 0.67 | 0.78 | 0.86 | 1.23 |
| Quick ratio | 1.19 | 0.67 | 0.78 | 0.86 | 0.89 |
| Working capital ratio | 3.9% | -3.8% | -4.2% | -2.6% | 14.7% |
| Solvency | 21.5% | 18.3% | 15.4% | 19.1% | 9.5% |
| Debt / equity | 3.65 | 4.45 | 5.49 | 4.23 | 2.90 |
| Long-term debt ratio | 2.70 | 3.78 | 4.19 | 3.22 | 2.90 |
| Interest coverage | 10.43 | 5.44 | 2.04 | 5.51 | - |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| ROA | 4.7% | 0.4% | -6.2% | 1.2% | 3.2% |
| ROE | 21.8% | 2.0% | -40.4% | 6.3% | 33.1% |
| EBITDA margin | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days inventory (DSI) | - | - | - | - | - |
Full annual accounts (27 line items)
| Line item | Code | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|---|
| Balance sheet, Assets | ||||||
| TOTAL ASSETS | 20/58 | €331k | €303k | €354k | €400k | €1.71M |
| Fixed assets | 21/28 | €250k | €280k | €301k | €335k | €384k |
| Intangible fixed assets | 21 | - | - | - | - | €2k |
| Tangible fixed assets | 22/27 | €250k | €280k | €301k | €335k | €382k |
| Financial fixed assets | 28 | - | - | - | - | €201 |
| Current assets | 29/58 | €80k | €23k | €54k | €65k | €1.32M |
| Stocks & contracts in progress | 3 | - | - | - | - | €375k |
| Amounts receivable within one year | 40/41 | €69k | €6k | €38k | €47k | €754k |
| Cash & bank | 54/58 | €11k | €15k | €12k | €15k | €191k |
| Balance sheet, Equity & liabilities | ||||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €331k | €303k | €354k | €400k | €1.71M |
| Equity | 10/15 | €71k | €56k | €55k | €77k | €162k |
| Contributions / capital | 10/11 | €19k | €19k | €19k | €19k | - |
| Reserves | 13 | €73k | €58k | €58k | €58k | €42k |
| Accumulated profits (losses) | 14 | €-21k | €-21k | €-22k | €0 | €2k |
| Provisions & deferred taxes | 16 | - | - | - | - | €0 |
| Amounts payable | 17/49 | €260k | €248k | €300k | €324k | €1.55M |
| Amounts payable after one year | 17 | €192k | €211k | €229k | €246k | €471k |
| Amounts payable within one year | 42/48 | €68k | €35k | €69k | €75k | €1.07M |
| Trade debts payable within one year | 44 | €15k | €6k | €20k | €12k | €466k |
| Income statement | ||||||
| Gross operating margin | 9900 | €55k | €39k | €19k | €57k | €410k |
| Operating result | 9901 | €26k | €8k | €-14k | €19k | €122k |
| Financial income | 75 | - | €0 | €2 | €20 | €7k |
| Financial charges | 65 | €5k | €7k | €8k | €9k | €34k |
| Result before taxes | 9903 | €21k | €1k | €-22k | €10k | €75k |
| Income taxes | 67/77 | €6k | €304 | €317 | €5k | €27k |
| Net result for the period | 9904 | €15k | €1k | €-22k | €5k | €48k |
| Result to be appropriated | 9905 | €15k | €1k | €-22k | €5k | €52k |
| NACE primary | Wholesale of pharmaceutical and medical goods(46460) |
| Legal form | Private limited company(610) |
| Incorporation | 09-12-2010 |
| Status | Active |
| Postal code | 9070 |
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44028D0495/00K000 | Flanders | 1,641 m² | 1 · 229 m² | - |
We know of 7 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
11-10-2021 Share split
Technical details
{
"events": [
{
"kind": "share_split",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"subscribers": [
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "VAN DE WALLE Dries",
"share_class": null,
"liberation_pct": 100.0,
"contribution_kind": null,
"n_shares_subscribed": 1500,
"contribution_amount_eur": null
}
],
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 1500,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Ann De Paepe",
"firm_city": null,
"firm_name": "DE PAEPE \u0026 VERHOEVE, geassocieerde notarissen",
"office_city": "Gent",
"is_associated": true
},
"act_meta": {
"language": "nl",
"pub_date": "2021-10-11",
"filing_date": "2021-09-30",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2021-09-17",
"unanimous": true,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0831.762.330",
"name_full": "PHARMA MORE",
"legal_form": "besloten vennootschap",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"expedition",
"plan financier",
"bankattest",
"verslag bedrijfsrevisor"
],
"shareholders_after": [
{
"kbo": null,
"pct": null,
"kind": "person",
"name": "VAN DE WALLE Dries",
"role": "aandeelhouder",
"n_shares": 1500,
"share_class": null
}
],
"share_classes_after": []
}| Legal nameNL | Pharma More Management |